Please check your internet connection and try again.
# Clobazam (Oral Formulation)
## Overview
Clobazam is a benzodiazepine derivative used as an adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS).
## Primary Indications
Adjunctive treatment of seizures in patients 2 years of age and older with Lennox-Gastaut syndrome (LGS).
## Adult Dosing
* **Initiation:** 5 mg twice daily.
* **Titration:** Increase dose by 5 mg to 10 mg every week based on clinical response and tolerability, up to a maximum of 20 mg twice daily.
* **Maintenance:** Doses may range from 10 mg to 20 mg twice daily.
## Pediatric Dosing (Ages 2 to <18 years)
* **Initiation:** 2.5 mg twice daily.
* **Titration:** Increase dose by 2.5 mg to 5 mg every week based on clinical response and tolerability.
* **Maintenance:** Doses typically range from 5 mg to 10 mg twice daily, not to exceed 20 mg twice daily.
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. No specific dosage adjustments are established, but consider lower starting doses and slower titration.
* **Renal Impairment:** Use with caution. No specific dosage adjustments are established, but consider lower starting doses and slower titration.
## Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
* Severe hepatic impairment.
## Adverse Effects
* **Common:** Somnolence, sedation, constipation, decreased appetite, lethargy, aggression, irritability, difficulty with coordination, abnormal gait, vomiting.
* **Serious:** Suicidal ideation and behavior, severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), respiratory depression, dependence and withdrawal symptoms, paradoxical reactions (e.g., excitation).
## Key Drug Interactions
* **CNS Depressants (e.g., alcohol, opioids, other benzodiazepines, sedating antihistamines):** Increased risk of sedation, respiratory depression, and CNS depression.
* **CYP3A4 Inducers (e.g., carbamazepine, phenytoin, rifampin):** May decrease clobazam concentrations.
* **CYP3A4 Inhibitors (e.g., ketoconazole, itraconazole):** May increase clobazam concentrations.
* **UGT2B7 Inhibitors (e.g., valproic acid):** May increase clobazam concentrations.
## Monitoring
* Monitor for efficacy (seizure frequency).
* Monitor for adverse effects, particularly somnolence, sedation, behavioral changes, and signs of suicidal ideation.
* Monitor for signs of withdrawal if the drug is discontinued.
* Consider monitoring clobazam and N-desmethylclobazam (active metabolite) levels, especially in cases of altered efficacy or increased adverse effects, although therapeutic ranges are not well-established.
## Clinical Pearls
* Clobazam has a longer half-life than many other benzodiazepines, which may allow for less frequent dosing but also increases the risk of accumulation.
* Withdrawal symptoms can occur upon abrupt discontinuation. Taper the dose gradually.
* Behavioral and psychiatric side effects, including suicidal ideation, can occur. Patients and caregivers should be informed of these risks and advised to report any changes in mood or behavior.
* This information is not a substitute for professional medical advice. Always consult the current prescribing information for complete details.
